Fri, Aug 29, 2014, 6:50 AM EDT - U.S. Markets open in 2 hrs 40 mins

Recent

% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

  • daaytradenot159 daaytradenot159 Mar 29, 2013 2:15 AM Flag

    George Zavoico interviewed by The Life Sciences Report

    TLSR: You and I talked about Threshold Pharmaceuticals in March and September of 2012. You have a $14.50 target price on the stock, which represents an implied triple for investors. Is this an 18-month target price?

    GZ: No, it's a 12-month target.

    TLSR: What is the catalyst expected to achieve that valuation?

    GZ: The catalyst is growing appreciation of the value of the company's hypoxia-activated prodrug, TH-302. The company has a number of trials underway, including one in sarcoma. While the pancreatic cancer trial has pretty much read out, phase 1 trials with TH-302 in several other indications will probably read out sometime in the course of the year. If results are positive, they will help validate the idea of going after hypoxic regions of tumors. As the company moves forward, I think investors will begin to appreciate that TH-302 is not just for a single indication but can be used more broadly across a number of cancers, since there are hypoxic regions in just about all solid tumors as well as in bone marrow in hematologic malignancies. In my mind, that justifies the $14.50 valuation.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Too many if and conditions. Phase 1 data is worth 10C increase at best. CURIS with approved drug is struggling. I think that the future is ASTX, CRIS (??) ONXX for sure (I had this since $4).
      CRIS has Q1 Roche great sales with potential to $4 by the end of next week. THLD belongs to the last century!!!!
      I just got back from AACR and will be at ASCO in May. Nothing to impressive but some of the big pharma had some good data.

    • The $14.50 price target is still less than a $1B market cap. When it becomes clear that TH-302 will be used extensively with the anti-angiogenics in numerous indications, $1B will seem paltry.

    • Did he copy this off some research report ? "ALL LOCKED UP".....what a hoot ! Go Dendreon ! Whats your target on THAT one ??? Has anybody told you the answer to that ?? Yahoo give you the answer ?
      Who's the seller ? Institutions ? Oh yeh.....they cant sell......all locked up ! Keeping searching for new reports to post.....

    • Toward the end of January the company announced that its partner, the EMD Serono division of German company Merck KGaA (MKGAY.PK), began a multicenter, randomized, double-blind, placebo-controlled phase 3 trial in 660 patients with TH-302 + gemcitabine, versus a control arm using placebo and gemcitabine. These patients have locally advanced, unresectable or metastatic pancreatic cancer. It's called the MAESTRO trial, and it's being conducted under the FDA's special protocol assessment process. Patients will remain in the trial unless there's evidence of disease progression or intolerance. This is a registrational study, and it will carry on until 508 events occur, meaning deaths, which will prompt a statistical analysis of the trial endpoints. If all goes as planned, and especially if the results reproduce the phase 2b outcome, we forecast that TH-302 could gain approval, and we could see a launch by the end of 2015, or perhaps in H1/16. The company could become profitable in 2016. Based on existing phase 2 data for TH-302 and phase 3 data for Celgene Corp.'s (CELG) Abraxane [paclitaxel protein-bound particles], which is not yet approved in pancreatic cancer, we believe TH-302 will have the edge on Abraxane in both safety and efficacy.

      Sentiment: Strong Buy

      • 1 Reply to daaytradenot159
      • Since Abraxane has not yet been approved for pancreatic cancer, we don't forecast much of an impact on recruitment in MAESTRO, despite its possible off-label use since it is approved for other cancers. We even consider it an opportunity, because a combination of Abraxane and TH-302, with or without gemcitabine, could prove to be even more efficacious than either drug when combined only with gemcitabine in a doublet.

        Hey Timmy !!! George says enrollment will go just fine for Maestro! Does that mean THLD won't need to look outside of the US for the " GLOBAL " phase 3 Pancreas trial ?

        Sentiment: Strong Buy

 
THLD
4.08-0.07(-1.69%)Aug 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Williams-Sonoma Inc.
NYSEThu, Aug 28, 2014 4:02 PM EDT
Veeva Systems Inc.
NYSEThu, Aug 28, 2014 4:01 PM EDT